A ARVINAS INC
| Market Cap | $856.11M |
| P/E Ratio | — |
| Forward P/E | -3.81 |
| Dividend Yield | — |
| Beta | 1.94 |
| 52W Range | $5.90 - $18.45 |
| # Hedge Funds | 0 |
| Sector | Healthcare |
| Industry | Biotechnology |
Hedge Fund Ownership
| Investor 0 | % of Portfolio Weight of this stock in the investor's portfolio | Value Total dollar value of the position | Shares Number of shares held | Activity Portfolio change type: New, Increased, Decreased, or Sold |
|---|
Insider Trading
| Insider Name of the company insider who made the trade 21 | Type Purchase (buy) or Sale (sell) | Shares Number of shares traded | Price Price per share at time of transaction | Value Total dollar value of the transaction | Trade Date Date the transaction was executed | Filing Date Date the SEC filing was submitted |
|---|---|---|---|---|---|---|
| Berkowitz NoahChief Medical Officer | Sale | 6,435 | $11.10 | $71.43K | 18 Mar 2026 | 18 Mar 2026 |
| Morrison Briggs | Buy | 20,000 | $13.40 | $268.07K | 06 Mar 2026 | 06 Mar 2026 |
| Houston John G | Sale | 4,688 | $13.24 | $62.07K | 27 Feb 2026 | 02 Mar 2026 |
| Houston John G | Sale | 11,787 | $13.14 | $154.88K | 27 Feb 2026 | 02 Mar 2026 |
| Houston John G | Sale | 18,822 | $13.24 | $249.20K | 27 Feb 2026 | 02 Mar 2026 |
| Angela M CacaceChief Scientific Officer | Sale | 1,038 | $12.16 | $12.62K | 23 Feb 2026 | 25 Feb 2026 |
| David K LoomisChief Accounting Officer | Sale | 1,108 | $12.16 | $13.47K | 23 Feb 2026 | 25 Feb 2026 |
| Angela M CacaceChief Scientific Officer | Sale | 2,571 | $12.16 | $31.26K | 23 Feb 2026 | 25 Feb 2026 |
| Randy TeelPresident and CEO | Sale | 3,748 | $12.16 | $45.58K | 23 Feb 2026 | 25 Feb 2026 |
| Randy TeelPresident and CEO | Sale | 1,038 | $12.16 | $12.62K | 23 Feb 2026 | 25 Feb 2026 |
| Cacace Angela MChief Scientific Officer | Sale | 2,571 | $12.16 | $31.26K | 23 Feb 2026 | 25 Feb 2026 |
| Cacace Angela MChief Scientific Officer | Sale | 1,038 | $12.16 | $12.62K | 23 Feb 2026 | 25 Feb 2026 |
| Loomis David KChief Accounting Officer | Sale | 1,108 | $12.16 | $13.47K | 23 Feb 2026 | 25 Feb 2026 |
| Teel RandyPresident and CEO | Sale | 3,748 | $12.16 | $45.58K | 23 Feb 2026 | 25 Feb 2026 |
| Teel RandyPresident and CEO | Sale | 1,038 | $12.16 | $12.62K | 23 Feb 2026 | 25 Feb 2026 |
| Loomis David KChief Accounting Officer | Sale | 1,016 | $11.89 | $12.08K | 13 Feb 2026 | 18 Feb 2026 |
| Teel RandyPresident and CEO | Sale | 4,403 | $11.89 | $52.35K | 13 Feb 2026 | 18 Feb 2026 |
| Cacace Angela MChief Scientific Officer | Sale | 4,592 | $11.89 | $54.60K | 13 Feb 2026 | 18 Feb 2026 |
| Saik AndrewChief Financial Officer | Sale | 5,134 | $11.89 | $61.04K | 13 Feb 2026 | 18 Feb 2026 |
| Berkowitz NoahChief Medical Officer | Sale | 5,685 | $11.89 | $67.59K | 13 Feb 2026 | 18 Feb 2026 |
| Loomis David KChief Accounting Officer | Sale | 230 | $9.89 | $2.27K | 07 Nov 2025 | 07 Nov 2025 |
Frequently Asked Questions
What is ARVN stock price today?
ARVINAS INC (ARVN) is currently trading at $13.33. The stock has a 52-week range of $5.90 to $18.45 and a market capitalization of $856.11M.
Is ARVN a good stock to buy in 2026?
ARVINAS INC has a P/E ratio of N/A (forward P/E: N/A), a dividend yield of none, and 1-year performance of -23.6%. 0 hedge funds hold this stock. Review the fundamentals and ownership data above to make an informed decision.
Are insiders buying or selling ARVN stock?
There have been 21 insider transactions for ARVN in recent months. Insider buys can signal management confidence, while sales may reflect diversification or personal financial planning. Check the Insider Trading section above for details.
How has ARVN stock performed over the past year?
ARVINAS INC (ARVN) has returned -23.6% over the past 12 months. The stock traded between $5.90 and $18.45 during this period, and is currently at $13.33.
Which hedge funds own ARVN (ARVINAS INC)?
0 tracked hedge funds currently hold ARVN in their portfolios as of the latest 13F filings. See the ownership table above for the complete list.
What is ARVN's market cap and valuation?
ARVINAS INC (ARVN) has a market capitalization of $856.11M. The trailing P/E ratio is N/A and forward P/E is N/A. The stock is classified in the Healthcare sector.
What is ARVN's revenue and profitability?
ARVINAS INC reported revenue of $262.60M with net income of N/A and a profit margin of N/A. The stock has a beta of 1.94.
What sector is ARVN in and who are its biggest institutional holders?
ARVINAS INC (ARVN) operates in the Healthcare sector. It is held by 0 tracked hedge funds. See the ownership table above for the complete list.